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Alphai adrenergic receptors in mesenteric arteries of rats with chronic
renal failure. In previous studies we have shown that patients or rats
with chronic renal failure display reduced blood pressure response to
norepinephrine (NE). This abnormality is related to the high levels of
parathyroid hormone (PTH) which stimulates vasodilator prostaglandin
production. To determine whether chronic renal failure (CRF) also
affects pressor response to NE through changes in the properties of
alpha1 adrenoceptors, we have measured plasma NE and the number of
binding sited (Bmax) and the KD of these receptors in isolated mesen-
teric arteries of normal CRF rats and of CRF rats previously parathy-
roidectomized (PTX). Plasma NE was greater (P < 0.01) in CRF than in
control (67 14 vs. 32 3.1 ng/dl), but it was not different from
CRF-PTX rats. The Bmax of alphai adrenoceptors was lower (P < 0.05)
in CRF than control (80 10 vs. 173 29 fmol/mg protein), but it was
similar in CRF and CRF-PTX rats. The KD was not significantly
different among the three groups of rats studied. The data show that the
number of alpha1 adrenoceptors is reduced in CRF and this is not
related to excess PTH. This abnormality may contribute to the reduced
pressor response to NE in CRF. The effect of PTH, on the vascular
response to NE is not related to changes in plasma levels of NE or in
binding sites for NE.
We have previously shown that patients with acute [1] or
advanced chronic renal failure (CRF) [2] and rats with 5/6
nephrectomy [3] display reduced blood pressure response to
norepinephrine (NE). The patients and animals displaying this
abnormality also had elevated plasma levels of NE [2, 4—9],
suggesting that down-regulation of the alpha1 adrenergic recep-
tors may be responsible for the reduced responsiveness to NE.
Several studies in our laboratory have indicated that this
abnormality may be related to the high blood levels of parathy-
roid hormone (PTH) [3, 10, 11], which is commonly seen in
chronic renal failure [12—15]. Studies in humans [10] and ani-
mals [3, lii showed that the effect of PTH on the response to
norepinephrine is mediated, at least in part, through stimulation
of the production of vasodilating protaglandins. Moreover,
parathyroidectomy normalized the response to NE in rats with
CRF [3].
It is possible that parathyroidectomy and prevention of
secondary hyperparathyroidism in CRF normalize the plasma
NE levels and, consequently, reverse the down-regulation of
alpha1 adrenergic receptors.
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The present studies were undertaken to examine the effect of
chronic renal insufficiency in the presence or absence of sec-
ondary hyperparathyroidism on the plasma levels of NE and on
the binding properties of alpha1 adrenoreceptors in mesenteric
arteries of rats with chronic renal failure.
Methods
Male Sprague-Dawley rats weighing 250 to 350 g were stud-
ied. They were fed normal purina rat chow (ICN nutritional
Biochemical, Cleveland, Ohio, USA) and housed in individual
cages. After anesthesia with intraperitoneal injection of 40 to 50
mg of sodium pentobarbital/kg body weight (Western Medical
Supply, Inc., Arcadia, California, USA), a group of rats under-
went parathyroidectomy (PTX) by electrocautery and the suc-
cess of the procedure was ascertained by a decrease in plasma
levels of calcium of at least 2 mg/dl. These rats were allowed to
drink water containing 5% of calcium gluconate. This procedure
is adequate to normalize plasma levels of calcium in PTX rats.
Another group of rats underwent sham-PTX. Seven days after
PTX or sham-PTX procedures, the animals underwent a right
nephrectomy; a week later partial left nephrectomy was per-
formed. A third group of rats comprised of sham-PTX animals
were not subjected to nephrectomy. Thus, this protocol in-
cluded three groups of rats, one with normal renal function and
two with chronic renal failure (CRF). Of the animals with CRF,
one group had intact parathyroid glands (CRF-sham PTX) and
the other was without parathyroid glands (CRF-PTX). The rats
were maintained in a state of CRF for six to eight weeks.
Measurement of plasma norepinephrine
Some of the rats were anesthetized with sodium pentobarbi-
tal, and the left carotid artery was cannulated with polyethylene
tubing (PE-50, Clay Adams, Parsipany, New Jersey, USA),
filled with solution of sodium heparin (1000 IU/ml in 0.9%
saline). The tubings were led subcutaneously to emerge at the
base of the neck; they were then threaded through a thin wire
spring (PGC Scientific Corp., Rockville, Maryland, USA), 20
cm long to protect the tubing. After surgery, the animals were
housed in individual cages and the tubings were passed through
the top of the cage to be connected to 1 ml plastic syringes with
a 23-gauge hypodermal needle. The following day, while the
rats were awake, unrestrained and undisturbed, with an ambi-
ent temperature of 20 to 22°C, two blood samples of 0.5 ml were
drawn two hours apart from each animal for measurement of
plasma NE. The blood drawn was replaced with equal volumes
463
464 Fadda et al. Alpha, adrenoceptors in CRF
Table 1. Body weight, serum creatinine, calcium, phosphorus and plasma norepinephrine (NE) levels in control rats and in rats with chronic
renal failure (CRF) with parathyroidectomy (PTX) or with sham-PTX
Body
(9)
wt
Serum levels
mg/dI NE
ng/dlCreatinine Calcium Phosphorus
Control 371 17 0.45 0.06 10,1 0.92 5.4 0.92 32.1 3.1
CRF-sham-PTX 353 13 1.9 0.4la 9.8 0.71 6.0 1.11 66.6 14.la
CRF-PTX 348 14 1.8 0.24a 10.0 0.82 7.1 0.98 68.9 17.6
a Significantly different from control with P < 0.01
of 0.9% saline. Plasma NE levels were assayed in duplicate by
the radioenzymatic method of DaPrada and Zurcher [161, with
the enzyme catechol-o-methyl transferase prepared according
to the method of Axeirod and Tomchick [171, and a methyl-
donor 3H-methyl-s-adenosine-methionine (New England Nu-
clear, Boston, Massachusetts, USA). The sensitivity of this
method is 1 pg for norepinephrine. The method is highly
specific. Among physiologic substances, only epinin and 3-4-
dihydroxyphenyl-glycol showed minimal interference. Mean
coefficient of intraassay and control plasma variations in 78
unselected consecutive determinations with this method were
5.1% and 12.1%, respectively.
Measurement of alpha, adrenergic receptors in mesenteric
vessels
Crude particulate fractions of mesenteric arteries were pre-
pared by modifications of the method of Wei, Janis and Daniel
US]. Following sacrifice by decapitation, the small intestine was
ligated proximally at the duodenum and distally at the terminal
ileum. The superior mesenteric vascular arcade was identified
near its origin at the aorta and the whole mesenteric arcade was
transferred, while still attached to the small intestine, into
ice-cold phosphate-buffered saline in a Petri dish. Removal of
most of the fat cells was accomplished by stripping of adhering
fatty tissue with forceps. The superior mesenteric vein, other
small veins, fat, and lymph nodes were discarded. Arteries
were placed in 10 ml of cold (4°C) 0.25 M sucrose solution (pH
= 6.1) in a Potter-Elvehjem homogenizer with a loose-fitting
Teflon pestle (0.004 to 0.006 inch clearance) and the fatty
tissues were removed with three gentle strokes. Arteries proc-
essed in this fashion were then combined in 50 ml cold (4OC)
0.25 M sucrose solution in a 60 ml beaker and coarsely minced
with scissors. The tissue was transferred to a 125 ml Erlen-
meyer flash and another 20 ml sucrose solution was added. The
tissue was homogenized with a Brinkman Polytron (setting 8, 10
sec X 2) and the solution was centrifuged at 900 g for 10 minutes
at 4°C, the pellet was discarded and the supernatant was then
centrifuged at 104,000 g in an ultracentrifuge (Model L 5-50,
Beckman Instruments Inc., Palo Alto, California, USA) for 30
minutes. The sediment was suspended in 1 to 1.5 ml assay
buffer (5 mai MgCl2, 50 miss Tris-HCL, pH 7.55). The mesen-
teric arteries from five to eight rats were combined to yield a
final protein concentration of 0.8 to 1.5 mglml. Protein concen-
tration was determined by the Lowry et al method with bovine
serum albumin as standard [19].
The alpha1-selective radiolabeled antagonist 2-[B(4 hydroxy-
phenol)-ethyl aminomethyl] tetralone, ['251]-HEAT was em-
ployed in a filtration assay along with phentolamine (l0— M).
Saturation binding isotherms were obtained by incubating 0.08
to 0.1 mg of freshly prepared particulate fractions at 30°C with
increasing concentrations of ['251]-HEAT (50 to 2000 pM) in a
final volume of 0.5 ml. Nonspecific binding was measured in
replicate tubes containing phentolamine (l0 M). Equilibrium
binding was carried out for 20 minutes in a rotary shaker bath at
180 rpm. Assays were terminated with the addition of 5 ml of
cold (4°C) assay buffer. Bound and free [1251]-HEAT were
separated by rapid filtration over glass fiber filters. Filters were
washed twice with an additional 8 ml of buffer. Radioactivity
retained in filters was measured in a gamma counter. Specific
binding was determined as the difference between total binding
and the binding measured in the presence of phentolamine (10—a
M). The (KD) and the number of these receptors (Bmax) were
derived from Scatchard plots [201. Serum calcium was deter-
mined by an atomic absorption spectrophotometer (Perkin-
Elmer Co., Model 503 Instrument Division, Norwalk, Connect-
icut, USA), and serum creatinine by Technicon Autoanalyzer
(Technicon Instrumentation Co., Tarrytown, New York, USA).
Statistical evaluation of the data was performed by analysis of
variance and by Newman-Keuls multiple range test.
Results
Table 1 presents the data on body weight, serum concentra-
tions of calcium and creatinine and plasma levels of norepineph-
rine in control, CRF-sham PTX and CRF-PTX animals. The 5/6
nephrectomy procedure was successful in producing CRF, as
evidenced by the rise in the serum levels of creatinine, and
these levels were not significantly different among the CRF-
sham PTX and CRF-PTX rats. There were no significant
differences in body weight and in serum concentrations of
calcium among the various groups of animals. Plasma NE was
significantly greater (P < 0.01) in CRF-sham PTX (67 14
ng/dl) than in control rats (32 3.1 ngldl). There was no
significant difference in plasma NE between CRF-sham PTX
and CRF-PTX (69 17.6 ng!dl). The Scatchard plot of the
binding properties of alpha adrenoceptors of mesenteric arter-
ies is shown in Figure 1. The Bmax of alpha1 adrenoceptors in
mesenteric arteries was significantly lower (P < 0.05) in CRF-
sham PTX (80 10 fmol/mg protein) and CRF-PTX (67 7
fmollmg protein) that in control rats (173 29 fmollmg protein).
The KD was not significantly different among the three groups
studied.
Discussion
The results of the present study indicate that chronic renal
failure is associated with pronounced changes in the density of
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Fig. 1. Scatchard plot of alphaj adrenoceptors in mesenteric arteries
of normal rats (0), rats with chronic renal failure () and rats with
chronic renal failure and prior parathyroidectomy (0). The Bmax Of
alpha1 adrenoceptors was significantly decreased (P < 0.05) in CRF and
CRF-PTX rats. The K was not significantly different among the three
groups.
alpha1 adrenergic receptors of mesenteric arteries of the rat.
Meggs et al [21] have also shown abnormalities of the binding
properties of alpha1 adrenoceptors in vascular smooth muscle
and myocardial membranes of rats with chronic renal failure.
Brodde and Daul showed a decrease in alpha2 adrenoceptors in
thrombocytes of uremic patients [22]. The mechanisms of these
abnormalities are not readily apparent; however, down regula-
tion of the alpha1 vascular receptors could be related to
increased sympathetic activity or to increased plasma levels of
NE. The latter possibility is most likely since plasma NE levels
are increased in the present study and in previous studies in
human subjects with chronic renal failure [1, 2, 4—8]. The
affinity of the receptors for the radioligand was not altered in
rats with chronic renal failure. The abnormality in the density of
alpha1 adrenoceptors is not related to excess PTH levels, since
it was not prevented by parathyroidectomy.
The physiologic implications of these observations are com-
plex. The reduced density of alpha1 adrenoceptors in arteries
may contribute to the reduced pressor response to endogenous
or infused NE in rats [3, 9] and humans [2] with chronic renal
failure. However, several lines of evidence suggest that the
reduced pressor response to NE may be related to excessive
production of vasodilator prostaglandins caused by the state of
secondary hyperparathyroidism of renal failure. First, an in-
verse relationship was found between the changes in blood
pressure during infusion of increasing doses of NE and the
serum levels of parathyroid hormone in patients with chronic
renal failure [10]. Administration of indomethacin prior to NE
infusion improved this abnormality. Second, administration of
PTH to normal rats increased urinary excretion of PGF1,,, a
metabolite of prostacycline, and blunted the pressor response
to NE; administration of indomethacin abolished the antagonis-
tic effects of PTH on the vascular response to NE in these
animals [11]. Finally, parathyroidectomy prevented the abnor-
mal response to NE in rats with chronic renal failure [3].
In the present study, parathyroidectomy did not alter the
plasma levels of norepinephrine in rats with chronic renal
failure. Despite the limitations of plasma norepinephrine as a
marker of sympathetic nerve activity, our data suggest that
parathyroidectomy does not alter the amount of neurotransmit-
ter produced and metabolized in rats with chronic renal failure.
Parathyroidectomy also failed to alter the binding properties of
adrenergic receptors in rats with chronic renal failure. Thus, the
improved pressor response to NE induced by parathyroidec-
tomy in rats with chronic renal failure cannot be attributed to
any significant interference of PTH with adrenergic activity and
binding properties of adrenergic receptors. Furthermore, the
present studies indicate that the decreased vascular response to
NE in uremia is not primarily related to down-regulation of
alpha1 adrenoceptors, since PTX corrects this abnormality
without altering the binding sites for NE.
It appears that the abnormal responsiveness to NE in uremia
may be dependent at least on two mechanisms: excessive
production of vasodilator prostaglandins caused by increased
blood levels of parathyroid hormone, and down-regulation of
alpha1 adrenoceptors. Under baseline conditions in CRF, nor-
mal cardiovascular homeostasis is maintained probably as a
consequence of increased blood levels of NE which may
overcome the increased production of prostacyclin, and the
down-regulation of adrenoceptors. However, it is tempting to
speculate that during NE infusion or during situations that
involve further activation of the sympathetic nervous system
(such as upright posture), the counter regulatory production of
prostaglandins may be exaggerated due to the state of second-
ary hyperparathyroidism. Such a sequence of events may
underlie the reduced response to NE and may lead to clinically
relevant symptoms, such as orthostatic hypotension. In CRF
without excess PTH, there may be no exaggerated production
of prostaglandins and hence appropriate response to NE. It is
also possible that a post-receptor defect develops in CRF due to
excess parathyroid hormone and that parathyroidectomy cor-
rects such abnormality.
It should be emphasized that our studies utilized mesenteric
arteries because they are richly innervated and, thus, are an
ideal tissue to study the vascular alpha1-receptors [23]; howev-
er, the alpha1 adrenergic receptors in these vessels may not be
necessarily the same as those found in all arteries. In addition,
it is also possible that down-regulation of alpha2 adrenergic
receptors is present in CRF and may be corrected by parathy-
roidectomy, but our studies did not test this possibility. The
demonstration that parathyroidectomy in CRF rats normalized
the pressor response to NE [3] without affecting the blood
levels of NE or the binding properties of alpha1-adrenoceptors
in mesenteric arteries, is consistent with these possibilities.
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